Navigation Links
Uroplasty Names David B. Perry Vice President Of Marketing
Date:12/10/2013

MINNEAPOLIS, Dec. 10, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced  that David B. Perry has joined the Company as Vice President of Marketing. He joins Uroplasty with nearly 20 years of experience developing, branding and commercializing medical device products resulting in market leadership, share gains and new sales opportunities in global markets.

"Dave's proven ability to develop and execute innovative  marketing strategies will be a valuable asset to our growth plans as we work towards both broadening and re-engaging our U.S. Urgent PC customer base of physicians," said Darin Hammers, Senior Vice President of Global Sales and Marketing. "His experience in revitalizing underperforming product lines and success in implementing revenue generating product strategies makes Dave an ideal fit for leveraging the initiatives already underway through our sales organization."

Mr. Perry's experience includes more than 10 years directing domestic and global product marketing initiatives in the endourology, prostate and men's health divisions at American Medical Systems (AMS), an Endo Health Solutions company. Prior to joining AMS, Mr. Perry held key marketing roles at Boston Scientific and Kendall Healthcare (Covidien, Inc.).

Mr. Perry holds a Bachelor of Science degree from Brigham Young University's Marriott School of Management.

About Overactive Bladder
Overactive bladder (OAB) is a chronic condition that affects approximately 34 million US adults.  The symptoms include urinary urgency, frequency and urge incontinence.  The Urgent PC Neuromodulation System is the only FDA cleared device that delivers Percutaneous Tibial Nerve Stimulation (PTNS) therapy.

About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:
Uroplasty, Inc.
Brett Reynolds, SVP and CFO
952.426.6152

EVC Group
Leigh Salvo (Investors)/Janine McCargo (Business Media)
415.568.9349/646.688.0245


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
2. Uroplasty Announces Product Development and New Clinical Trial Initiatives
3. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2012 Financial Results
4. Uroplasty To Present At The JMP Securities Healthcare Conference
5. Uroplasty to Issue First Quarter of Fiscal 2013 Financial Results on July 26, 2012
6. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
7. Uroplasty To Participate In Two Upcoming Conferences
8. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
9. Uroplasty To Participate In Two Upcoming Investor Conferences
10. Uroplasty To Participate In The Oppenheimer 23rd Annual Healthcare Conference
11. Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... LAWRENCEVILLE, N.J. , May 2, 2016 /PRNewswire/ ... drug development company, today announced data from the ... dose escalating clinical trial (the OVATION Study) combining ... of care for the treatment of newly-diagnosed patients ... chemotherapy followed by interval debulking surgery.  In the ...
(Date:4/29/2016)... , April 29, 2016 ... H1 2016" market research report that provides an ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology ... appointment of Dr. Alfredo Zurlo as Chief ... with many years clinical experience and a proven track ... role was at Mologen AG where he was Chief ... Dr. Zurlo held various positions at F Hoffmann La ...
Breaking Medicine Technology:
(Date:5/3/2016)... , ... May 03, 2016 , ... ... announced that it has been honored as one of the nation’s most accomplished ... InformationWeek Elite 100. Horizon received the recognition for technology achievements that have enabled ...
(Date:5/3/2016)... ... May 03, 2016 , ... BioPlus Specialty Pharmacy ... at the 2016 Asembia Specialty Pharmacy Summit held May 2-6, 2016 at the ... health care conference for the specialty pharmacy industry, with thousands of pharmacy providers, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Empyrean Benefit Solutions, Inc., the ... service center in La Vergne, Tennessee, near Nashville. The new center will complement ... Empyrean client services. , “Our Nashville-area center allows us to achieve several goals,” ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Park Cities ... live in or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, 75229, ... Greenway Parks, Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities areas ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... one of Canada’s top Information and Communication Technology (ICT) companies in the annual ... Multinational ICT companies operating in Canada, as ranked by revenue. , “We ...
Breaking Medicine News(10 mins):